FDA Approved: OFEV — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for OFEV (nintedanib) from Boehringer Ingelheim Pharmaceuticals, Inc., potentially resulting in a label update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• OFEV (Nintedanib)

Snippet

SUPPL AP for OFEV (NINTEDANIB)